Alzheimer’s disease (AD) is devastating for affected families and represents a major challenge for national healthcare systems, particularly as life expectancy continues to rise. We still lack therapeutic tools capable of providing—even if not a cure—at least a slowing of disease progression. Early intervention would limit brain damage and therefore offer greater benefit to patients. Thus, effective therapy is intrinsically linked to diagnostic advances, and the availability of biomarkers—proteins detectable in biological fluids—is of great importance.
Moreover, information obtained from fluid biomarkers must faithfully reflect the changes occurring in the brain; therefore, alterations detected in fluids must be validated in models, ideally human models. In summary, a biomarker must be useful for early disease detection and for monitoring progression or therapeutic response, including in cellular (or animal) models.
Proteins related to AD, such as β‑amyloid (Aβ) and tau, have shown diagnostic potential but limited prognostic value. These proteins are central to the two hallmark pathological processes of AD: the formation of senile plaques (Aβ) and neurofibrillary tangles (hyperphosphorylated tau). Changes in these biomarkers in cerebrospinal fluid (CSF) can be difficult to interpret—particularly for Aβ—throughout disease progression; tau (and P‑tau) exhibit high sensitivity but limited specificity. Distinguishing AD from other dementias is essential, as is differentiating AD subtypes, which may require distinct therapeutic approaches. A clear example is the presentation of psychotic symptoms in certain AD subtypes.
For years, our group has been investigating the interaction between Aβ and tau, focusing specifically on the apolipoprotein E (apoE) signalling pathway. ApoE—particularly its apoE4 variant—is the most important genetic risk factor for AD; carrying one copy of apoE4 doubles the risk of developing the disease, while carrying two copies increases it more than tenfold. The reason why this apoE variant confers such a high risk remains unknown. We hypothesise that apoE4 is the least effective isoform in performing its biological function of interacting with receptors to internalise signals. In this project, we aim to advance our research on defective apoE signalling in AD, with a particular focus on its relationship with β‑amyloid generation, which we believe promotes a harmful feedback loop driving disease progression. We will also explore how other APP‑derived fragments contribute to positive autoregulation, potentially opening avenues for new therapeutic strategies. Our research has always been grounded in data obtained from the brains of AD patients, and we also have extensive experience analysing these proteins in CSF to optimise their diagnostic utility. We characterise subtle alterations (post‑translational modifications) that help refine biomarker potential. By optimising protocols to study synaptic alterations in specific proteins in the brain, we also expect to develop new biomarkers. To understand and validate our findings, we plan to reproduce pathological dynamics in a human model: induced pluripotent stem cells (iPSCs), from which we can generate different brain cell types. This is particularly relevant because apoE is produced in astrocytes, whereas its receptors are expressed in neurons and microglia. We have iPSC lines engineered to carry different apoE variants, enabling us to study and understand the differences between apoE4 and other isoforms. In summary, two decades of research place us at a point where we believe our work can meaningfully contribute to deciphering pathological and therapeutic mechanisms, as well as to designing tools that benefit diagnosis and patient monitoring. For scientists working on this disease, it is essential not only to share our findings with the scientific community but also with society at large. We have participated—and plan to continue participating—in outreach activities related to our advances and to AD in general. Our recent findings have received broad media coverage. The UMH Institute of Neuroscience benefits from the support of science journalists who assist with dissemination on social media, in collaboration with ISABIAL’s communication team. Our involvement in CIBERNED will further facilitate these outreach efforts. We also have experience giving talks to patient associations and the general public, maintaining close contact with local AFAs.

